Wed Sep 25 03:18:47 UTC 2024: ## DexCom Stock Upgraded to “Buy” by StockNews.com

**San Francisco, CA** – DexCom (NASDAQ:DXCM), a leading medical device company specializing in continuous glucose monitoring (CGM) systems, received a positive rating upgrade from StockNews.com on Tuesday, September 24th. The research firm lifted its rating on DexCom from “Hold” to “Buy,” indicating a bullish outlook on the company’s future performance.

This upgrade comes amidst mixed signals from other analysts. While Robert W. Baird maintained a “Neutral” rating on the stock, JPMorgan Chase & Co. downgraded their rating to “Neutral” and lowered their price target. UBS Group and Oppenheimer, however, both maintained “Buy” and “Outperform” ratings, respectively, albeit with reduced price targets.

Despite the differing views, DexCom’s recent quarterly earnings report fueled optimism. The company reported earnings per share of $0.43, exceeding analysts’ expectations by $0.04. Revenue also reached $1 billion, demonstrating strong year-over-year growth of 15.3%.

While insider trading activity showed some selling of shares, institutional investors have been steadily increasing their stakes in DexCom. This suggests strong confidence in the company’s long-term prospects.

DexCom remains focused on providing innovative CGM solutions for diabetes management. Their portfolio includes the Dexcom G6 and Dexcom G7 systems, along with remote monitoring and third-party integration features.

The “Moderate Buy” rating assigned to DexCom by MarketBeat.com, coupled with the average target price of $112.25, reflects the overall positive sentiment surrounding the company.

**Investors should consult with a financial advisor before making any investment decisions based on this news article.**

Read More